

## CELL THERAPY

**CRISPR/Cas9-edited HSPC therapy for hemoglobinopathies**Humbert, O. et al. *Sci. Transl. Med.* **11**, eaaw3768 (2019)

$\beta$ -hemoglobinopathies are inherited disorders caused by mutations in the  $\beta$ -globin gene. Sickle cell disease, for example, is the result of deficient hemoglobin (Hb); patients with  $\beta$ -thalassemia produce insufficient amounts of the oxygen-carrying protein. To date, allogeneic transplantation of hematopoietic stem and progenitor cells (HSPC) is the only curative treatment available for hemoglobinopathies, but alternative therapeutic approaches are under investigation. One promising option is to use gene-editing technologies to reactivate fetal Hb (HbF); HbF can then act as a substitute for aberrant adult Hb. The findings of a new study describing persistent HbF reactivation after engraftment of CRISPR/Cas9-edited CD34<sup>+</sup> HSPC in a nonhuman primate (NHP) autologous transplantation model might bring us a step closer to the clinical translation of gene-edited HSPC therapy to patients.

The gene-editing strategy was designed to generate mutations in the HbF-associated locus (HBG) containing the binding site for B-cell lymphoma/leukemia 11A (BCL11A),

an HbF repressor controlling the fetal to adult Hb switch. Three rhesus macaques were infused with CRISPR/Cas9-treated CD34<sup>+</sup> HSPCs after total body irradiation. The number of gene-edited nucleated cells stabilized after 1 month (8–27% of cells in peripheral blood (PB) during the entire follow-up period of > 1 year), resulting in persistent HbF reactivation in transplanted animals. Compared with control transplant recipients showing <1.5% of cells expressing HbF (F cells) in PB at 250 days after treatment, all CRISPR/Cas9-edited animals expressed 6–18% of F cells during follow-up. HbF reactivation was further confirmed by longitudinal measurement of  $\gamma$ -globin with high-performance liquid chromatography (HPLC).

Similar results were observed in a second cohort of three rhesus macaques infused with a CRISPR/Cas9-edited stem cell-enriched CD34<sup>+</sup> subpopulation of CD34<sup>+</sup>CD90<sup>+</sup>CD45RA<sup>-</sup> cells, although the number of gene-edited cells transplanted in the second cohort was reduced by

10 fold. These results confirm that the CD34<sup>+</sup>CD90<sup>+</sup>CD45RA<sup>-</sup> subset is the main cell type contributing to multilineage long-term engraftment. Targeting that subset could be a new strategy to reduce the need for editing reagents without affecting engraftment, hematopoietic reconstitution, or HbF reactivation.

So far, the transplanted rhesus animals have been monitored for up to 1.5 years with no adverse effects detected. In the discussion of the study, the investigators conclude: “The conservation of the CD34<sup>+</sup>CD90<sup>+</sup>CD45RA<sup>-</sup> phenotype and the HBG CRISPR-Cas9 gRNA target site between NHP and human, combined with the use of a highly clinically relevant large-animal model for stem cell gene therapy and transplantation, should facilitate the direct translation of this approach to patients.”

Alexandra Le Bras




Published online: 9 September 2019  
<https://doi.org/10.1038/s41684-019-0406-7>



## WHO PERFORMS EYE EXAMS FOR YOUR STUDIES?



Board certified veterinary ophthalmologists are uniquely qualified to consult in the development of the experimental design, including the species selected, appropriate diagnostic tests, and frequency of exams. Coordination between the testing agency and the board certified veterinary ophthalmologist is essential throughout the process, to include protocol development, Standard Operating Procedures (SOP), and assessment of the outcome of testing.



Contact information for ACVO consultants: [office19@ACVO.org](mailto:office19@ACVO.org)

ACVO.org

PO Box 1311

Meridian, ID 83680

208-466-7624